FDA Grants Kymriah Advanced Treatment for Sefolioma Regenerative Medicine (RMAT)
-
Last Update: 2020-06-24
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Novartis today announced that the U.SFood and Drug Administration (FDA) has awarded Kymriah ® advanced regenerative medicine (RMAT) for treatment of recurrent lysopatomer (r/r) follicle-based lymphoma (FL)Kymriah ® is an FDA-approved CAR-T cell therapyRelapse is likely to be Kymriah's third indication"This finding will support the development of Kymriah, which could potentially improve the survival of some patients with follicular lymphoma," said John Tsai, director and chief medical officer of Global Drug Development at Novartisoffollicular lymphoma (FL) is the second most common form of non-Hodgkin's lymphoma (NHL), an inert lymphoma that accounts for about 22 percent of NHL casesAlthough new treatments can improve overall survival, FL is considered an incurable malignancyIn patients with recurrent FL throughout their life cycle, they may receive 5-12 line of previous treatment, and in most cases, relapsed FL patients tend to exhaust treatment options
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
